13 results on '"Gabriella Gainaru"'
Search Results
2. P1121: POSITRON EMISSION TOMOGRAPHY FOR FINAL RESPONSE ASSESSMENT TO RITUXIMAB-DOSE ADJUSTED EPOCH IN PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA: WHO IS WORTHY TO BE IRRADIATED?
- Author
-
Theodoros Vassilakopoulos, Alexia Piperidou, Zois Melios, Evgenia Verigou, Eirini Katodritou, Christina Kalpadakis, Sotirios Papageorgiou, Chrysovalantou Chatzidimitriou, Vassilios Prassopoulos, Marina Siakantaris, Hara Giatra, Dimitrios Kalkanis, Nikolaos Papathanasiou, Loukia Ligdi, Anastasia Kopsaftopoulou, Theoni Leonidopoulou, Vasileios Xanthopoulos, Stamatios Karakatsanis, Effimia Vrakidou, Sophia Chatziioannou, Dimitrios Drougkas, Eleftheria Hatzimichael, Gabriella Gainaru, Maria Palassopoulou, Maria Tsirogianni, Maria Kotsopoulou, Evangelia Skoura, Catherine Mainta, Evangelos Terpos, Christos Poziopoulos, Panayiotis Zikos, Argyro Koumarianou, Dimitra Liapi, Evgenia Verrou, Panayiotis Tsirigotis, Athanasios Liaskas, Maria Aikaterini Lefaki, Theodora Triantafylloy, Angeliki Georgopoulou, Vassiliki Labropoulou, Helen Papadaki, Ioannis Datseris, Argyris Symeonidis, Maria Bouzani, Themis Karmiris, Maria Bakiri, Maria Angelopoulou, and Phivi Rontogianni
- Subjects
Diseases of the blood and blood-forming organs ,RC633-647.5 - Published
- 2023
- Full Text
- View/download PDF
3. Real-life Experience With Rituximab-CHOP Every 21 or 14 Days in Primary Mediastinal Large B-cell Lymphoma
- Author
-
STAMATIS J. KARAKATSANIS, MARIA BOUZANI, ARGYRIS SYMEONIDIS, MARIA K. ANGELOPOULOU, SOTIRIOS G. PAPAGEORGIOU, MICHAIL MICHAIL, GABRIELLA GAINARU, GEORGIA KOURTI, SOTIRIOS SACHANAS, CHRISTINA KALPADAKIS, EIRINI KATODRITOU, THEONI LEONIDOPOULOU, IOANNIS KOTSIANIDIS, ELEFTHERIA HATZIMICHAEL, MARIA KOTSOPOULOU, MARIA DIMOU, ELENI VARIAMIS, DIMITRIOS BOUTSIS, NICK KANELLIAS, MARIA N. DIMOPOULOU, EVRIDIKI MICHALI, GEORGE KARIANAKIS, PANTELIS TSIRKINIDIS, CHRYSSA VADIKOLIA, CHRISTOS POZIOPOULOS, ANNA PIGADITOU, EFFIMIA VRAKIDOU, THEOPHANIS ECONOMOPOULOS, LYDIA KYRIAZOPOULOU, MARINA P. SIAKANTARIS, MARIE-CHRISTINE KYRTSONIS, KONSTANTINOS ANARGYROU, MARIA PAPAIOANNOU, EVDOXIA HATJIHARISSI, ELISSAVET VERVESSOU, MARIA TSIROGIANNI, MARIA PALASSOPOULOU, EKATERINI STEFANOUDAKI, PANAYIOTIS ZIKOS, PANAYIOTIS TSIRIGOTIS, GERASSIMOS TSOUROUFLIS, THEODORA ASSIMAKOPOULOU, EVGENIA VERROU, HELEN PAPADAKI, POLIXENI LAMPROPOULOU, MELETIOS-ATHANASIOS DIMOPOULOS, VASSILIKI PAPPA, KOSTAS KONSTANTOPOULOS, THEMIS KARMIRIS, PARASKEVI ROUSSOU, PANAYIOTIS PANAYIOTIDIS, GERASSIMOS A. PANGALIS, and THEODOROS P. VASSILAKOPOULOS
- Subjects
Pharmacology ,Cancer Research ,Lymphoma, B-Cell ,General Biochemistry, Genetics and Molecular Biology ,immune system diseases ,Doxorubicin ,Vincristine ,hemic and lymphatic diseases ,Antineoplastic Combined Chemotherapy Protocols ,Humans ,Prednisone ,Prospective Studies ,Rituximab ,Cyclophosphamide ,Research Article ,Retrospective Studies - Abstract
Background/Aim: Primary mediastinal large B-cell lymphoma (PMLBCL) is an aggressive B-cell non-Hodgkin lymphoma (NHL), whose prognosis has greatly improved since the incorporation of the anti-CD20 monoclonal antibody rituximab into current therapeutic regimens. Evidence, however, on the optimal time interval between consecutive chemoimmunotherapy (CIT) cycles is still scarce. This study aimed to evaluate the efficacy outcomes of the more commonly administered 3-weekly regimens to the biweekly ones in a PMLBCL patients’ population, who were mostly treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone every 21 days (R-CHOP-21) or R-CHOP-14. Patients and Methods: We retrospectively studied our cohort of consecutively treated PMLBCL patients, focusing on their treatment density, in order to determine possible differences in treatment outcomes. Results: CIT, in the form of both R-CHOP-21 as well as R-CHOP-14 (or similar regimens), is highly active in PMLBCL, with low rates of early treatment failure. In our cohort of patients, R-CHOP-14 did not result in a meaningful improvement of freedom from progression (FFP) or overall survival (OS). Conclusion: Both R-CHOP-14 and R-CHOP-21 are probably equally effective in PMLBCL, yet further, prospective, randomized studies are warranted to clarify whether dose-dense regimens can be associated with better disease control and long-term results.
- Published
- 2022
4. RITUXIMAB‐DOSE‐ADJUSTED EPOCH (R‐DA‐EPOCH) IN PRIMARY MEDIASTINAL LARGE B‐CELL LYMPHOMA (PMLBCL): REAL‐LIFE EXPERIENCE ON 190 PATIENTS FROM 3 MEDITERRANEAN COUNTRIES
- Author
-
A. Koumarianou, Argyris Symeonidis, Leylagül Kaynar, Saime Paydas, Nikolaos Kanellias, Chezi Ganzel, G. Isenberg, Themistoklis Karmiris, Olga Meltem Akay, E. Megalakaki, M. Ozgur, George Karianakis, Eleftheria Hatzimichael, Miri Zektser, M. Palassopoulou, Eirini Katodritou, O. Gutwein, Chrysovalantou Chatzidimitriou, Stamatios Karakatsanis, Maria Tsirogianni, Tulin Firatli Tuglular, Maria K. Angelopoulou, Z. Mellios, Anat Gafter-Gvili, Effimia Vrakidou, T.P. Vassilakopoulos, Gabriella Gainaru, Christina Kalpadakis, A. C. Atalar, Ronit Gurion, Marina P. Siakantaris, Panayiotis Tsirigotis, Panagiotis Zikos, Sotirios G. Papageorgiou, Burhan Ferhanoglu, Theoni Leonidopoulou, Tamar Tadmor, Netanel A. Horowitz, and A. Piperidou
- Subjects
Cancer Research ,medicine.medical_specialty ,Oncology ,business.industry ,medicine ,Rituximab ,Primary Mediastinal Large B-Cell Lymphoma ,Hematology ,General Medicine ,EPOCH (chemotherapy) ,Radiology ,business ,medicine.drug - Published
- 2021
5. Positron emission tomography after response to rituximab-CHOP in primary mediastinal large B-cell lymphoma: impact on outcomes and radiotherapy strategies
- Author
-
Themis Karmiris, Zois Mellios, Maria Kotsopoulou, Konstantinos Anargyrou, George Karianakis, Eleftheria Hatzimichael, Gerassimos A. Pangalis, Phivi Rondogianni, Evangelos Terpos, Stamatios Karakatsanis, Argyris Symeonidis, Theodoros P. Vassilakopoulos, Eirini Katodritou, Pavlina Konstantinidou, Catherine Mainta, Pantelis Tsirkinidis, Sotirios G. Papageorgiou, Theoni Leonidopoulou, Panagiotis Tsirigotis, Ioannis Kotsianidis, Christina Kalpadakis, Ioannis Datseris, Evridiki Michali, Marie-Christine Kyrtsonis, Anna Pigaditou, Maria K. Angelopoulou, Eleni Variamis, Maria Dimou, Helen A. Papadaki, Meletios-Athanassios Dimopoulos, Maria Arapaki, Effimia Vrakidou, Gabriella Gainaru, Paraskevi Roussou, Vassiliki Pappa, Vassilios Prassopoulos, Christos Poziopoulos, Marina P. Siakantaris, Theodora Assimakopoulou, S. Chatziioannou, Elissavet Vervessou, Dimitrios Boutsis, Kostas Konstantopoulos, Evdoxia Chatziharissi, Maria Papaioannou, Maria Palassopoulou, Chryssa Vadikolia, Maria Tsirogianni, Panayiotis Panayiotidis, and Sotirios Sachanas
- Subjects
PET-CT ,medicine.medical_specialty ,medicine.diagnostic_test ,business.industry ,medicine.medical_treatment ,Mediastinum ,Retrospective cohort study ,Hematology ,General Medicine ,CHOP ,medicine.disease ,Lymphoma ,Radiation therapy ,03 medical and health sciences ,0302 clinical medicine ,medicine.anatomical_structure ,Positron emission tomography ,030220 oncology & carcinogenesis ,medicine ,Rituximab ,Radiology ,business ,030215 immunology ,medicine.drug - Abstract
End-of-treatment (EoT) PET/CT is used as a guide to omit radiotherapy (RT) patients with primary mediastinal large B-cell lymphoma (PMBCL). We present the mature and extended results of a retrospective study evaluating the prognostic significance of EoT-PET/CT after adequate response to R-CHOP. Among 231 consecutive PMLBCL patients, 182 underwent EoT-PET/CT and were evaluated according to the Deauville 5-point scale (D5PS) criteria. Freedom from progression (FFP) was measured from the time of PET/CT examination. Among 182 patients, 72 (40%) had D5PS score 1 (D5PSS-1), 33 (18%) had 2, 28 (15%) had 3, 29 (16%) had 4, and 20 (11%) had 5. The 5-year FFP was 97, 94, 92, 82, and 44% for D5PSS-1, D5PSS-2, D5PSS-3, D5PSS-4, and D5PSS-5, respectively. Among 105 patients with unequivocally negative PET/CT (D5PSS-1/D5PSS-2), 49 (47%) received RT (median dose 3420 cGy) and 56 (53%) did not with relapses in 0/49 vs. 4/56 patients (2 mediastinum and 2 isolated CNS relapses).The 5-year FFP for those who received RT or not was 100% versus 96%, when isolated CNS relapses were censored (p = 0.159). Among D5PSS-3 patients (27/28 irradiated-median dose 3600 cGy), the 5-year FFP was 92%. The 5-year FFP for D5PSS-4 and D5PSS-5 was 82 and 44%; 44/49 patients received RT (median dose 4000 and 4400 cGy for D5PSS-4 and D5PSS-5). Our study supports the omission of RT in a sizeable fraction of PET/CT-negative patients and definitely discourages salvage chemotherapy and ASCT in patients with PMLBCL who conventionally respond to R-CHOP, solely based on PET/CT positivity in the absence of documented progressive or multifocal disease. The persistence of positive PET/CT with D5PSS < 5 after consolidative RT should not trigger the initiation of further salvage chemotherapy in the absence of conventionally defined PD.
- Published
- 2021
6. Positron emission tomography after response to rituximab-CHOP in primary mediastinal large B-cell lymphoma: impact on outcomes and radiotherapy strategies
- Author
-
Theodoros P, Vassilakopoulos, Sotirios G, Papageorgiou, Maria K, Angelopoulou, Sophia, Chatziioannou, Vassilios, Prassopoulos, Stamatios, Karakatsanis, Maria, Arapaki, Zois, Mellios, Sotirios, Sachanas, Christina, Kalpadakis, Eirini, Katodritou, Theoni, Leonidopoulou, Ioannis, Kotsianidis, Eleftheria, Hatzimichael, Maria, Kotsopoulou, Maria, Dimou, Eleni, Variamis, Dimitrios, Boutsis, Evangelos, Terpos, Evridiki, Michali, George, Karianakis, Pantelis, Tsirkinidis, Chryssa, Vadikolia, Christos, Poziopoulos, Anna, Pigaditou, Effimia, Vrakidou, Marina P, Siakantaris, Marie-Christine, Kyrtsonis, Argyris, Symeonidis, Konstantinos, Anargyrou, Maria, Papaioannou, Evdoxia, Chatziharissi, Elissavet, Vervessou, Maria, Tsirogianni, Maria, Palassopoulou, Gabriella, Gainaru, Catherine, Mainta, Panagiotis, Tsirigotis, Theodora, Assimakopoulou, Pavlina, Konstantinidou, Helen, Papadaki, Meletios-Athanassios, Dimopoulos, Vassiliki, Pappa, Themis, Karmiris, Paraskevi, Roussou, Ioannis, Datseris, Panayiotis, Panayiotidis, Kostas, Konstantopoulos, Gerassimos A, Pangalis, and Phivi, Rondogianni
- Subjects
Adult ,Male ,Adolescent ,Middle Aged ,Mediastinal Neoplasms ,Young Adult ,Treatment Outcome ,Doxorubicin ,Vincristine ,Positron Emission Tomography Computed Tomography ,Antineoplastic Combined Chemotherapy Protocols ,Humans ,Prednisone ,Female ,Lymphoma, Large B-Cell, Diffuse ,Rituximab ,Cyclophosphamide ,Aged ,Retrospective Studies - Abstract
End-of-treatment (EoT) PET/CT is used as a guide to omit radiotherapy (RT) patients with primary mediastinal large B-cell lymphoma (PMBCL). We present the mature and extended results of a retrospective study evaluating the prognostic significance of EoT-PET/CT after adequate response to R-CHOP. Among 231 consecutive PMLBCL patients, 182 underwent EoT-PET/CT and were evaluated according to the Deauville 5-point scale (D5PS) criteria. Freedom from progression (FFP) was measured from the time of PET/CT examination. Among 182 patients, 72 (40%) had D5PS score 1 (D5PSS-1), 33 (18%) had 2, 28 (15%) had 3, 29 (16%) had 4, and 20 (11%) had 5. The 5-year FFP was 97, 94, 92, 82, and 44% for D5PSS-1, D5PSS-2, D5PSS-3, D5PSS-4, and D5PSS-5, respectively. Among 105 patients with unequivocally negative PET/CT (D5PSS-1/D5PSS-2), 49 (47%) received RT (median dose 3420 cGy) and 56 (53%) did not with relapses in 0/49 vs. 4/56 patients (2 mediastinum and 2 isolated CNS relapses).The 5-year FFP for those who received RT or not was 100% versus 96%, when isolated CNS relapses were censored (p = 0.159). Among D5PSS-3 patients (27/28 irradiated-median dose 3600 cGy), the 5-year FFP was 92%. The 5-year FFP for D5PSS-4 and D5PSS-5 was 82 and 44%; 44/49 patients received RT (median dose 4000 and 4400 cGy for D5PSS-4 and D5PSS-5). Our study supports the omission of RT in a sizeable fraction of PET/CT-negative patients and definitely discourages salvage chemotherapy and ASCT in patients with PMLBCL who conventionally respond to R-CHOP, solely based on PET/CT positivity in the absence of documented progressive or multifocal disease. The persistence of positive PET/CT with D5PSS5 after consolidative RT should not trigger the initiation of further salvage chemotherapy in the absence of conventionally defined PD.
- Published
- 2020
7. Identification of Very Low-Risk Subgroups of Patients with Primary Mediastinal Large B-Cell Lymphoma Treated with R-CHOP
- Author
-
Konstantinos Anargyrou, George Karianakis, Maria Kotsopoulou, Eleftheria Hatzimichael, Pavlina Konstantinidou, Maria Papaioannou, Chryssa Vadikolia, Evangelos Terpos, Katerina Megalakaki, Lydia Kyriazopoulou, Stamatios Karakatsanis, Anna Pigaditou, Theoni Leonidopoulou, Maria Dimou, Eleni Variamis, Michail Michail, Dimitrios Boutsis, Effimia Vrakidou, Gabriella Gainaru, Pantelis Tsirkinidis, Ioannis Kotsianidis, Kostas Konstantopoulos, Paraskevi Roussou, Maria N. Dimopoulou, Maria Palassopoulou, Theodora Assimakopoulou, Panayiotis Tsirigotis, Christina Kalpadakis, Maria K. Angelopoulou, Gerasimos Tsourouflis, Vassiliki Pappa, Evdoxia Hatjiharissi, Sotirios G. Papageorgiou, Theophanis Economopoulos, Themis Karmiris, Argyris Symeonidis, Meletios-Athanasios Dimopoulos, Christos Poziopoulos, Eirini Katodritou, Ekaterini Stefanoudaki, Panayiotis Zikos, Helen A. Papadaki, Marina P. Siakantaris, Theodoros P. Vassilakopoulos, G. Kourti, Maria Tsirogianni, Gerassimos A. Pangalis, Eurydiki Michalis, Panayiotis Panayiotidis, Sotirios Sachanas, Elissavet Vervessou, Marie-Christine Kyrtsonis, and Fotios Panitsas
- Subjects
Adult ,Cancer Research ,medicine.medical_specialty ,Multivariate analysis ,Hematologic Malignancies ,CHOP ,Gastroenterology ,Extranodal Disease ,03 medical and health sciences ,0302 clinical medicine ,International Prognostic Index ,Internal medicine ,hemic and lymphatic diseases ,Antineoplastic Combined Chemotherapy Protocols ,Medicine ,Humans ,EPOCH (chemotherapy) ,Extranodal Involvement ,Cyclophosphamide ,business.industry ,medicine.disease ,Prognosis ,Lymphoma ,Oncology ,Doxorubicin ,Vincristine ,030220 oncology & carcinogenesis ,Prednisone ,Rituximab ,Lymphoma, Large B-Cell, Diffuse ,business ,030215 immunology ,medicine.drug - Abstract
Background R-CHOP can cure approximately 75% of patients with primary mediastinal large B-cell lymphoma (PMLBCL), but prognostic factors have not been sufficiently evaluated yet. R-da- EPOCH is potentially more effective but also more toxic than R-CHOP. Reliable prognostic classification is needed to guide treatment decisions. Materials and Methods We analyzed the impact of clinical prognostic factors on the outcome of 332 PMLBCL patients ≤65 years treated with R-CHOP ± radiotherapy in a multicenter setting in Greece and Cyprus. Results With a median follow-up of 69 months, 5-year freedom from progression (FFP) was 78% and 5-year lymphoma specific survival (LSS) was 89%. On multivariate analysis, extranodal involvement (E/IV) and lactate dehydrogenase (LDH) ≥2 times upper limit of normal (model A) were significantly associated with FFP; E/IV and bulky disease (model B) were associated with LSS. Both models performed better than the International Prognostic Index (IPI) and the age-adjusted IPI by Harrel's C rank parameter and Akaike information criterion. Both models A and B defined high-risk subgroups (13%–27% of patients [pts]) with approximately 19%–23% lymphoma-related mortality. They also defined subgroups composing approximately one-fourth or one-half of the patients, with 11% risk of failure and only 1% or 4% 5-year lymphoma-related mortality. Conclusion The combination of E/IV with either bulky disease or LDH ≥2 times upper limit of normal defined high-risk but not very-high-risk subgroups. More importantly, their absence defined subgroups comprising approximately one-fourth or one-half of the pts, with 11% risk of failure and minimal lymphoma-related mortality, who may not need more intensive treatment such as R-da-EPOCH. Implications for Practice By analyzing the impact of baseline clinical characteristics on outcomes of a large cohort of patients with primary mediastinal large B-cell lymphoma homogeneously treated with R-CHOP with or without radiotherapy, we developed novel prognostic indices which can aid in deciding which patients can be adequately treated with R-CHOP and do not need more intensive regimens such as R-da-EPOCH. The new indices consist of objectively determined characteristics (extranodal disease or stage IV, bulky disease, and markedly elevated serum lactate dehydrogenase), which are readily available from standard initial staging procedures and offer better discrimination compared with established risk scores (International Prognostic Index [IPI] and age-adjusted IPI).
- Published
- 2020
8. PROGNOSTIC FACTORS (PFs) IN PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMLBCL) TREATED WITH RITUXIMAB-CHOP (RCHOP) ± RADIOTHERAPY (RT)
- Author
-
Ioannis Kotsianidis, Paraskevi Roussou, Dimitrios Boutsis, Gerasimos Pangalis, Eirini Katodritou, Pavlina Konstantinidou, M.A. Dimopoulos, Konstantinos Anargyrou, Anna Pigaditou, Maria Kotsopoulou, E. Hadjiharissi, Evridiki Michali, Ekaterini Stefanoudaki, Argyris Symeonidis, Sotirios G. Papageorgiou, Vassiliki Pappa, P. Panayitidis, George Karianakis, Themistoklis Karmiris, Eleni Variami, Chryssa Vadikolia, Christos Poziopoulos, Theoni Leonidopoulou, Maria Tsirogianni, G. Kourti, Michail Michail, Sotirios Sachanas, Konstantinos Konstantopoulos, Maria Papaioannou, Effimia Vrakidou, T.P. Vassilakopoulos, Gabriella Gainaru, Maria K. Angelopoulou, Christina Kalpadakis, and E. Terpos
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,business.industry ,medicine.medical_treatment ,Hematology ,General Medicine ,CHOP ,Radiation therapy ,Internal medicine ,medicine ,Primary Mediastinal Large B-Cell Lymphoma ,Rituximab ,business ,medicine.drug - Published
- 2019
9. PF297 COMPARISON OF RITUXIMAB DOSE-ADJUSTED EPOCH (R-DA-EPOCH) WITH RITUXIMAB-CHOP (R-CHOP) CHEMOTHERAPY IN PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMLBCL)
- Author
-
T. Giannikos, Konstantinos Konstantopoulos, E. Constaninou, A. Liaskas, K. Sakellariou, Z. Mellios, I. Assimakopoulos, M. Bellia, D. Grentzelias, George Karianakis, T.P. Vassilakopoulos, Gabriella Gainaru, Themistoklis Karmiris, E. Katrodritou, Eleni Plata, Theoni Leonidopoulou, Sotirios G. Papageorgiou, Theodora Assimakopoulou, Eleni Papadaki, V. Xanthopoulos, Maria Tsirogianni, Stamatios Karakatsanis, P. Katsaouni, H. Giatra, Chrysovalantou Chatzidimitriou, Maria K. Angelopoulou, Christina Kalpadakis, Argyris Symeonidis, Vassiliki Pappa, Evgenia Verigou, Maria Arapaki, G. Kourti, and M. Bakiri
- Subjects
Oncology ,medicine.medical_specialty ,business.industry ,Internal medicine ,R-CHOP chemotherapy ,medicine ,Rituximab ,Primary Mediastinal Large B-Cell Lymphoma ,Hematology ,EPOCH (chemotherapy) ,CHOP ,business ,medicine.drug - Published
- 2019
10. The Significance of PET/CT in the Initial Staging of Hodgkin Lymphoma: Experience Outside Clinical Trials
- Author
-
Sotirios Sachanas, Maria K. Angelopoulou, George Boutsikas, Gerassimos A. Pangalis, Theodoros P. Vassilakopoulos, John V. Asimakopoulos, Gabriella Gainaru, Sofia Chatziioannou, Phoivi Rondogianni, Maria Arapaki, Marie-Christine Kyrtsonis, Kostas Konstantopoulos, P Panayiotidis, Vassilios Prassopoulos, Iliana Konstantinou, Marina P. Siakantaris, Maria Moschogianni, Gerasimos Tsourouflis, Xanthi Yiakoumis, Eftychia Mosa, Ioannis E. Datseris, and Pantelis Tsirkinidis
- Subjects
Adult ,Male ,Time Factors ,Adolescent ,Standardized uptake value ,Kaplan-Meier Estimate ,Disease-Free Survival ,Lesion ,03 medical and health sciences ,Young Adult ,0302 clinical medicine ,Predictive Value of Tests ,Positron Emission Tomography Computed Tomography ,Medicine ,Humans ,030212 general & internal medicine ,Young adult ,Aged ,Neoplasm Staging ,Retrospective Studies ,Aged, 80 and over ,PET-CT ,business.industry ,Reproducibility of Results ,Retrospective cohort study ,Middle Aged ,Hodgkin Disease ,Clinical trial ,Treatment Outcome ,030220 oncology & carcinogenesis ,Predictive value of tests ,Female ,Tomography ,medicine.symptom ,business ,Nuclear medicine - Abstract
AIM To examine the real-life impact of baseline positron-emission tomography/computed tomography (PET/CT) in Hodgkin lymphoma (HL). PATIENTS AND METHODS A total of 162 consecutive patients with HL were retrospectively studied. RESULTS Disease was up-staged in 26 patients (16%) and down-staged in 9 (6%). However, treatment strategy was modified in only 10 patients (6% of total). Involved field radiotherapy was delineated according to PET/CT in 36/66 patients (59%). These treatment modifications did not significantly affect outcome. Moreover, three potent prognostic parameters were identified: the number of involved sites, maximum standardized uptake value (SUVmax), and the product of SUVmax and maximal largest lesion diameter, as a surrogate of total lesion glycolysis. All three significantly correlated with 5-year freedom from disease progression p=0.004, p=0.009 and p=0.04, respectively). CONCLUSION Baseline PET/CT findings may lead to treatment modification in
- Published
- 2017
11. PS1089 PET-SCAN FOR RESPONSE ASSESSEMENT AFTER RITUXIMAB-DOSE-ADJUSTED-EPOCH (R-DA-EPOCH) IN PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMLBCL): CLINICAL AND PROGNOSTIC SIGNIFICANCE
- Author
-
E. Plata, Z. Mellios, Evgenia Verigou, C. Kalpadakis, Gabriella Gainaru, S. Karatsanis, K. Themistoklis, Eleni Papadaki, I. Datseris, K. Konstantopoulos, Maria Arapaki, K. Sakellariou, D. Grentzelias, Theodoros P. Vassilakopoulos, Sotirios G. Papageorgiou, T. Giannikos, G. Karanakis, E. Katodritou, A. Koumarianou, S. Chatziioannou, M. Bakiri, Chrysovalantou Chatzidimitriou, V. Xanthopoulos, M. Efstathopoulou, V. Prassopoulos, P. Rontogianni, M. K. Angelopoulou, H. Giatra, Maria Tsirogianni, and A. Simeonidis
- Subjects
medicine.medical_specialty ,business.industry ,Medicine ,Rituximab ,Primary Mediastinal Large B-Cell Lymphoma ,Hematology ,EPOCH (chemotherapy) ,Radiology ,business ,medicine.drug - Published
- 2019
12. Prognostic Implication of the Absolute Lymphocyte to Absolute Monocyte Count Ratio in Patients With Classical Hodgkin Lymphoma Treated With Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine or Equivalent Regimens
- Author
-
Pagona Flevari, Maria N. Dimopoulou, Xanthoula Yiakoumis, Konstas Konstantopoulos, Kyriaki Petevi, Gabriella Gainaru, Maria Dimou, Panayiotis Tsaftaridis, Eleni Plata, Nora-Athina Viniou, Alexandros Kanellopoulos, George Boutsikas, Katerina Koutsi, Loula Papageorgiou, John Meletis, Panayiotis Panayiotidis, Sotirios Sachanas, Pantelis Tsirkinidis, Maria K. Angelopoulou, Eleni Variami, Gerassimos A. Pangalis, Vassilios Telonis, Maria Moschogiannis, Marie-Christine Kyrtsonis, Marina P. Siakantaris, and Theodoros P. Vassilakopoulos
- Subjects
musculoskeletal diseases ,Adult ,Male ,Cancer Research ,medicine.medical_specialty ,Pathology ,Adolescent ,Lymphocyte ,Dacarbazine ,Hematologic Malignancies ,Bleomycin ,Vinblastine ,Gastroenterology ,Monocytes ,03 medical and health sciences ,chemistry.chemical_compound ,Young Adult ,0302 clinical medicine ,Monocytosis ,Internal medicine ,Lymphopenia ,Antineoplastic Combined Chemotherapy Protocols ,Medicine ,Humans ,Doxorubicin ,Lymphocyte Count ,Lymphocytes ,Aged ,Retrospective Studies ,Aged, 80 and over ,business.industry ,Middle Aged ,medicine.disease ,Hodgkin's lymphoma ,Combined Modality Therapy ,Hodgkin Disease ,medicine.anatomical_structure ,Oncology ,chemistry ,030220 oncology & carcinogenesis ,Female ,Lymphocytopenia ,business ,030215 immunology ,medicine.drug - Abstract
Low absolute lymphocyte count (ALC) to absolute monocyte count (AMC) ratio (ALC/AMC) is an independent prognostic factor in Hodgkin lymphoma (HL), but different cutoffs (1.1, 1.5, and 2.9) have been applied. We aimed to validate the prognostic significance of ALC/AMC in 537 homogenously treated (doxorubicin, bleomycin, vinblastine, and dacarbazine or equivalents ± radiotherapy) classical HL patients at various cutoffs. The median ALC/AMC was 2.24 (0.44–20.50). The median AMC was 0.653 × 109/L (0.050–2.070). Lower ALC/AMC was associated with established markers of adverse prognosis. In total, 477 (89%), 418 (78%), and 189 (35%) patients had an ALC/AMC ratio of ≥1.1, ≥1.5, and ≥2.9; respectively; 20% had monocytosis (≥0.9 × 109/L). Ten-year time to progression (TTP) was 77% versus 55% for patients with ALC/AMC ≥1.1 and
- Published
- 2016
13. Potential role of AKT/mTOR signalling proteins in hairy cell leukaemia: association with BRAF/ERK activation and clinical outcome
- Author
-
Theodoros P. Vassilakopoulos, Georgia Levidou, Christina Kalpadakis, Irene Thymara, Christina Piperi, Christos Adamopoulos, Angelica A. Saetta, Gerassimos A. Pangalis, Athanasia Sepsa, Efstratios Patsouris, Maria Moschogiannis, Eleftheria Lakiotaki, Penelope Korkolopoulou, Maria K. Angelopoulou, Pagona Flevari, Nikolaos Tsesmetzis, Gabriella Gainaru, Eleni Plata, Ilenia Chatziandreou, Panayiotis Panayiotidis, Sotirios Sachanas, Konstantinos Konstantopoulos, George Z. Rassidakis, Vassilios Milionis, and Maria N. Dimopoulou
- Subjects
0301 basic medicine ,MAPK/ERK pathway ,Proto-Oncogene Proteins B-raf ,medicine.medical_specialty ,Proto-Oncogene Proteins c-akt ,DNA Mutational Analysis ,Gene Expression ,Kaplan-Meier Estimate ,Biology ,Article ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,medicine ,Extracellular Signal-Regulated MAP Kinases ,Protein kinase B ,PI3K/AKT/mTOR pathway ,Proportional Hazards Models ,Mitogen-Activated Protein Kinase 1 ,Leukemia, Hairy Cell ,Multidisciplinary ,Mitogen-Activated Protein Kinase 3 ,Caspase 3 ,TOR Serine-Threonine Kinases ,RPTOR ,Transfection ,Patient Outcome Assessment ,030104 developmental biology ,Endocrinology ,030220 oncology & carcinogenesis ,Mutation ,Cancer research ,Hairy Cell ,Signal transduction ,Biomarkers ,Signal Transduction - Abstract
The potential role of AKT/mTOR signalling proteins and its association with the Raf-MEK-ERK pathway was investigated in hairy cell leukaemia (HCL). BRAFV600E expression and activated forms of AKT, mTOR, ERK1/2, p70S6k and 4E-BP1 were immunohistochemically assessed in 77 BM biopsies of HCL patients and correlated with clinicopathological and BM microvascular characteristics, as well as with c-Caspase-3 levels in hairy cells. Additionally, we tested rapamycin treatment response of BONNA-12 wild-type cells or transfected with BRAFV600E. Most HCL cases expressed p-p70S6K and p-4E-BP1 but not p-mTOR, being accompanied by p-ERK1/2 and p-AKT. AKT/mTOR activation was evident in BONNA-12 cells irrespective of the presence of BRAFV600E mutation and was implicated in cell proliferation enhancement. In multivariate analysis p-AKT/p-mTOR/p-4E-BP1 overexpression was an adverse prognostic factor for time to next treatment conferring earlier relapse. When p-AKT, p-mTOR and p-4E-BP1 were examined separately only p-4E-BP1 remained significant. Our findings indicate that in HCL, critical proteins up- and downstream of mTOR are activated. Moreover, the strong associations with Raf-MEK-ERK signalling imply a possible biologic interaction between these pathways. Most importantly, expression of p-4E-BP1 alone or combined with p-AKT and p-mTOR is of prognostic value in patients with HCL.
- Published
- 2015
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.